Regulatory News
Tuesday, December 27, 2016
BRIEF-Immunomedics achieves patient enrollment for single-arm Phase 2 study with sacituzumab govitecan
* Immunomedics announces achievement of patient enrollment
into single-arm phase 2 study with sacituzumab govitecan
(immu-132) in triple-negative breast cancer
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment